IgA Nephropathy

Could adding serum C3 and C4 levels to existing predictive models for IgA nephropathy (IgAN) improve their accuracy?

Could the systemic inflammatory response index (SIRI) be a useful measure of renal prognosis in IgA nephropathy (IgAN)?

Diffuse magnetic imaging resonance shows promise for evaluating clinical and pathological changes in patients with IgAN.

Purespring Therapeutics received $105M in Series B funding to develop gene therapies for kidney diseases, including IgAN.

Long-term results of a study of atacicept to treat IgA nephropathy (IgAN) will be presented at ASN Kidney Week.

It is important to know the risks versus benefits of a reduced-dose methylprednisolone regimen in high-risk IgAN patients.

Patients with both IgAN and C2 lesions displayed a poor clinical prognosis requiring more effective treatment strategies.

There is a need to identify prognostic biomarkers of IgA nephropathy (IgAN) that can be used in clinical practice.

Researchers developed an updated pediatric prediction tool to determine risk for IgA nephropathy (IgAN) post-biopsy.

Researchers studied the prognostic value of a new inflammatory biomarker, the systemic immune inflammation index, in IgAN.

Knowledge Hubs